|
Balance Sheet Cash Flow Statement 730 Stockton Dr. Exton, PA 19341 PA Tel. 610-458-7300 Fax 610-458-7380 |
Type: Public
On the web:
http://www.viropharma.com
Employees:
201
Employee growth: 74.8%
ViroPharma didn't want to wait until its drugs were approved to start making money, so instead it bought an approved one. The development-stage firm discovers drugs to combat RNA viruses, a category that includes cytomegalovirus (CMV) in transplant patients and gastrointestinal infections. To finance its development, however, the company acquired the antibiotic Vancocin, which treats conditions of staph and other infections, from Eli Lilly. Vancocin is distributed through wholesalers in the US. The company also markets Cinryze, a drug made from human plasma to combat angiodema (swelling of the skin or hives).
Key numbers for fiscal year ending December, 2008:
Sales: $232.3M
One year growth: 14.0%
Net income: $67.6M
Income growth: (29.1%)
Officers:
Chairman, President, and CEO: Vincent J. (Vinnie) Milano
VP, COO, and Chief Commercial Officer: Daniel B. (Dan) Soland
VP and CFO: Charles A. (Charlie) Rowland Jr.
Competitors:
Cubist Pharmaceuticals
Roche Holding
Teva Pharmaceuticals
